About this trial
The purpose of this study is to determine if combining a virtual diabetes self-management program (DECIDE®) with continuous glucose monitoring (CGM) is practical and well-received by adults with type 2 diabetes. Twenty participants will attend the 9-week, virtual DECIDE Self-Management Program. They will receive CGM sensors to wear during the 22-week study to track their blood sugar. Participants will complete questionnaires at three time points -- at baseline, 1 week after the DECIDE Program ends, and 3 months after the DECIDE Program ends. They will also complete a blood draw to measure hemoglobin A1C at baseline and 3 months after the intervention ends. Additionally, they will complete a brief interview after the program ends to gather insights into participants' experiences with the program. The study aims to examine whether this integrated approach will be both feasible and acceptable, potentially leading to better diabetes management and improved health outcomes.
Eligibility criteria
Qualifiers
Aged 18 years or older
Diagnosis of type 2 diabetes
Suboptimal hemoglobin A1C (8.0% or greater) based on a laboratory result in the past 3 months
Access to and capability of using a smart cellular device
Disqualifiers
Currently using CGM
Non-English speaking
Unavailable to attend the virtual DECIDE group
Unavailable for follow-up
Trial design
Treatments tested in this trial
- The DECIDE Self-Management Program
- Continuous Glucose Monitoring (CGM)
Treatment groups
Sponsors and collaborators
Northwell Health
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Albert Einstein College of Medicine
Collaborator